

## Exploring Clinical Investigator Perspectives on the Optimal Management of Multiple Myeloma (Medical and Hematologic Oncologists)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following progression-free survival outcomes was reported at the ASCO 2020 virtual meeting on the Phase III ENDURANCE (ECOG-E1A11) trial evaluating carfilzomib, lenalidomide and dexamethasone (KRd) versus lenalidomide, bortezomib and dexamethasone (RVd) as initial therapy for patients with MM?**
  - a. KRd was inferior to RVd
  - b. KRd was noninferior or equivalent to RVd**
  - c. KRd was superior to RVd
- 2. What was observed in the randomized Phase II GRIFFIN trial comparing daratumumab with RVd to RVd alone for patients with newly diagnosed MM who were eligible for autologous stem cell transplant?**
  - a. Improved complete response rates with daratumumab only
  - b. Higher rate of MRD negativity with daratumumab only
  - c. Both a and b**
- 3. Which of the following drug types best describes the mechanism of action of the novel agents iberdomide and CC-92480?**
  - a. Anti-CD38 antibody
  - b. Bcl-2-targeted agent
  - c. B-cell maturation antigen (BCMA)-targeted agent
  - d. Cereblon E3 ligase modulator ("CELMoD")**
- 4. Initial results reported at the ASCO 2020 virtual meeting from the Phase II KarMMa trial evaluating the investigational BCMA-directed CAR T-cell immunotherapy idecabtagene vicleucel (ide-cel) for patients with relapsed/refractory, heavily pretreated MM included which of the following outcomes?**
  - a. Deep, durable responses with ide-cel
  - b. A favorable clinical benefit-risk profile for ide-cel across the range of target doses
  - c. Both a and b**
  - d. Neither a nor b
- 5. What was observed in the Phase II DREAMM-2 study among patients with heavily pretreated MM who received the antibody-drug conjugate belantamab mafodotin?**
  - a. Unacceptably high rates of Grade 5 adverse events
  - b. A low overall response rate (<20%)
  - c. Frequent ocular toxicities**